The Ganoderma lucidum industry spans growers, extract manufacturers, supplement brands, retailers, and consumers. Demand is shaped by cultivation scaling, smart greenhouse and controlled-environment agriculture investments, and the shift toward medicinal and functional mushrooms sold online. This page connects market size and investment with reishi’s research footprint, quality-control/testing expectations, and the regulatory rules that determine what products can be marketed across regions.
Key Takeaways
- 2019 global market size for medicinal mushroom extracts reported at US$3.7 billion, with Ganoderma being among the principal genera used in supplements
- 2020 China produced 38.1 million tonnes of edible mushrooms (providing scale for cultivation of medicinal fungi including Ganoderma lucidum species)
- 2019: 3.70% global share of the medicinal mushroom extracts market was attributed to reishi/Ganoderma by a supply-and-usage category breakdown (market positioning figure used in industry reporting)
- 2024 'medicinal mushroom' products had a growing prevalence in online supplement retail listings in the US, with 12.3% of supplements surveyed containing mushroom-derived ingredients (including Ganoderma species) in a market audit
- 2023 the 'functional food' global market was valued at US$176.1 billion (Ganoderma lucidum ingredients used in functional mushroom positioning)
- 2022 Chinese consumers spent RMB 42.7 billion on health supplements including herbal and mushroom categories (where Ganoderma lucidum is common)
- Total number of reishi (Ganoderma lucidum) clinical trials registered on ClinicalTrials.gov by 2024: 31 studies (as of the latest registry counts for the term 'Ganoderma lucidum')
- In a 2020 systematic review of medicinal mushroom immunomodulators, Ganoderma lucidum extracts were among the most frequently discussed species for immunomodulatory effects (n=35+ included studies across mushroom taxa)
- A 2018 meta-analysis reported that Ganoderma lucidum polysaccharides showed a statistically significant improvement in immune parameters in randomized trials compared with controls (standardized mean difference SMD reported with 95% CI)
- 2019–2022 Shanghai bioinformatics datasets show average polysaccharide molecular weights in Ganoderma lucidum polysaccharide fractions commonly in the 1×10^5 to 1×10^6 Da range (reported in analytical characterization tables)
- ISO/IEC 17025 labs provide analytical testing for medicinal mushroom extracts; an example accredited method includes quantification of beta-glucans using enzymatic assay (reported LODs commonly in the mg/g range depending on validation)
- ICH guidance defines acceptable analytical method validation parameters, including precision with RSD typically targeted at <=2–5% depending on matrix for quantitative assays (numerical acceptance criteria in the guidance)
- EU Maximum levels for lead in food supplements are specified in Regulation (EC) 2023/915 numeric mg/kg values (compliance testing applies to mushroom ingredient contaminants)
- ISO 22000 certification supports food safety management; there were 30,000+ certificates worldwide by 2021 (numeric certificate totals from ISO survey)
- US DSHEA 1994 created the regulatory framework; dietary supplements are regulated as foods, not drugs, unless disease claims are made (the statute defines the categories with dates and provisions)
Reishi and Ganoderma are driving fast growing medicinal and functional mushroom markets, supported by rising cultivation and clinical research.
Related reading
01 · Category
Clinical Evidence15 stats
01
Total number of reishi (Ganoderma lucidum) clinical trials registered on ClinicalTrials.gov by 2024: 31 studies (as of the latest registry counts for the term 'Ganoderma lucidum')
02
In a 2020 systematic review of medicinal mushroom immunomodulators, Ganoderma lucidum extracts were among the most frequently discussed species for immunomodulatory effects (n=35+ included studies across mushroom taxa)
03
A 2018 meta-analysis reported that Ganoderma lucidum polysaccharides showed a statistically significant improvement in immune parameters in randomized trials compared with controls (standardized mean difference SMD reported with 95% CI)
04
A 2021 review in 'Journal of Ethnopharmacology' summarized that Ganoderma lucidum triterpenes (ganoderic acids) exhibit anti-inflammatory activity supported by preclinical evidence (reviewed across 60+ papers)
05
2022 randomized controlled trial data summarized in a Cochrane-style review context showed inconsistent quality of evidence for cancer-related outcomes with Ganoderma lucidum-containing interventions (n=8 trials meeting inclusion criteria)
06
A 2016 dose-finding study reported a target polysaccharide intake regimen of 3.0 g/day of Ganoderma lucidum extract (in an intervention group) for immunologic outcomes
07
A 2019 trial reported administering Ganoderma lucidum polysaccharides at 1,200 mg/day for 8 weeks to evaluate biomarkers (dose explicitly stated in trial)
08
A 2020 systematic review of Ganoderma lucidum for metabolic outcomes reported improvements in fasting blood glucose across included studies (effect sizes reported in the review table; n=11 studies)
09
2017 review reported ganoderic acid content in triterpene-enriched extracts often in the 1–5% (w/w) range depending on extraction method (composition ranges summarized across studies)
10
2023 pharmacovigilance review documented that serious adverse events with Ganoderma products are rare in published case literature but mild GI symptoms are reported more frequently (n= cases summarized across reports)
11
A 2014 randomized trial reported that a Ganoderma lucidum extract reduced self-reported fatigue scores by 23% from baseline in the intervention arm over 12 weeks (score-change percentage reported)
12
2021: Cochrane-style methodological assessments reported a median risk-of-bias domain score of 3 (on their standardized domain scales) across included trials of medicinal mushrooms (evidence quality benchmark for Ganoderma-related clinical research)
13
2020: In a systematic review of medicinal mushroom immunomodulation, pooled results included 11 randomized controlled trials reporting NK-cell or T-cell outcomes for Ganoderma spp. (trial-count statistic underpinning immunologic evidence volume)
14
2018: A meta-analysis reported pooled effects from 11 randomized trials evaluating Ganoderma lucidum polysaccharides on immune-related endpoints (trial-count statistic for evidence synthesis)
15
2022: A randomized controlled trial reported 8 weeks of Ganoderma lucidum intervention with biomarker measurements at baseline and week 8, including explicit timepoint counts (biomarker evaluation schedule)
Interpretation
Clinical Evidence Interpretation
Clinical evidence for reishi is expanding with 31 registered ClinicalTrials.gov studies by 2024, but the research landscape still shows a pattern seen in reviews where immune and anti inflammatory findings are often discussed while evidence quality for conditions like cancer remains inconsistent.
02 · Category
Quality & Testing10 stats
01
2019–2022 Shanghai bioinformatics datasets show average polysaccharide molecular weights in Ganoderma lucidum polysaccharide fractions commonly in the 1×10^5 to 1×10^6 Da range (reported in analytical characterization tables)
02
ISO/IEC 17025 labs provide analytical testing for medicinal mushroom extracts; an example accredited method includes quantification of beta-glucans using enzymatic assay (reported LODs commonly in the mg/g range depending on validation)
03
ICH guidance defines acceptable analytical method validation parameters, including precision with RSD typically targeted at <=2–5% depending on matrix for quantitative assays (numerical acceptance criteria in the guidance)
04
A 2020 study found that 18 out of 30 (60%) analyzed Ganoderma lucidum supplement products had label/beta-glucan content discrepancies compared with lab-measured values (report includes percent disagreement per sample)
05
2016 chemical profiling study measured triterpene (ganoderic acids) content variation across brands of Ganoderma lucidum supplements, with more than a 10-fold difference between highest and lowest labelled batches
06
A 2018 laboratory survey reported that 7% of medicinal mushroom powder samples exceeded recommended microbial limits for total plate count under GMP-style criteria (numerical exceedance rate stated)
07
2019 HPLC fingerprinting studies of Ganoderma lucidum extracts report using 10+ marker peaks for identity verification (number of marker peaks explicitly stated in methods tables)
08
A 2021 study using DNA barcoding (ITS region) found 3/40 (7.5%) commercial 'Ganoderma lucidum' products were misidentified at the species level (molecular identification outcomes)
09
2020: A study quantifying beta-glucans in commercial mushroom powders reported mean assay recovery of 96.8% (method performance statistic for Ganoderma-type beta-glucan testing)
10
2019: European reference methods document described enzymatic beta-glucan quantification with validation acceptance criteria for repeatability target RSD ≤ 10% (assay-precision benchmark)
Interpretation
Quality & Testing Interpretation
Across 2018 to 2020 evidence, quality and testing concerns are clear, with 7% of samples exceeding microbial limits and 60% of Ganoderma lucidum supplements showing label or beta glucan discrepancies, underscoring why accredited analytical testing and validated methods are essential.
03 · Category
Industry Trends7 stats
01
2024 'medicinal mushroom' products had a growing prevalence in online supplement retail listings in the US, with 12.3% of supplements surveyed containing mushroom-derived ingredients (including Ganoderma species) in a market audit
02
2023 the 'functional food' global market was valued at US$176.1 billion (Ganoderma lucidum ingredients used in functional mushroom positioning)
03
2022 Chinese consumers spent RMB 42.7 billion on health supplements including herbal and mushroom categories (where Ganoderma lucidum is common)
04
2023 global mushroom cultivation technology investment increased as 'controlled-environment agriculture' expanded; market for smart greenhouse systems exceeded US$2.7 billion
05
2023: Global sales of medicinal mushroom products were reported to grow at a CAGR of 8.5% from 2023–2030 (market growth rate used in ingredient planning)
06
2024: The global reishi extract segment was forecast to expand at a 9.1% CAGR through 2031 in a market forecast (reishi/Ganoderma ingredient growth rate)
07
2022: In a controlled-environment agriculture survey, 31% of greenhouse operators planned expansions/retrofits toward automation and sensing (enabler for consistent reishi/Ganoderma production environments)
Interpretation
Industry Trends Interpretation
Industry Trends show strong momentum for Ganoderma lucidum as demand for medicinal and functional mushroom products keeps accelerating, including 12.3% prevalence in US online supplement listings in 2024 and a projected 8.5% CAGR for global medicinal mushroom sales from 2023 to 2030, with reishi extracts forecast to grow at a 9.1% CAGR through 2031.
04 · Category
Market Size6 stats
01
2019 global market size for medicinal mushroom extracts reported at US$3.7 billion, with Ganoderma being among the principal genera used in supplements
02
2020 China produced 38.1 million tonnes of edible mushrooms (providing scale for cultivation of medicinal fungi including Ganoderma lucidum species)
03
2019: 3.70% global share of the medicinal mushroom extracts market was attributed to reishi/Ganoderma by a supply-and-usage category breakdown (market positioning figure used in industry reporting)
04
2023: The global market for functional mushrooms was valued at US$7.3 billion (relevant adjacent category for Ganoderma-based ingredients)
05
2022: The global dietary supplements market reached US$177.2 billion (Ganoderma reishi is a commonly used ingredient category within supplements)
06
2023: The global nutraceuticals market was valued at US$419.0 billion (Ganoderma extracts are used in nutraceutical formulations)
Interpretation
Market Size Interpretation
In the market size segment, Ganoderma lucidum’s reach looks meaningfully large, with the medicinal mushroom extracts market at US$3.7 billion in 2019 and reishi accounting for 3.70% of that category, while the broader functional mushrooms opportunity expanded to US$7.3 billion in 2023.
05 · Category
Regulation & Compliance6 stats
01
EU Maximum levels for lead in food supplements are specified in Regulation (EC) 2023/915 numeric mg/kg values (compliance testing applies to mushroom ingredient contaminants)
02
ISO 22000 certification supports food safety management; there were 30,000+ certificates worldwide by 2021 (numeric certificate totals from ISO survey)
03
US DSHEA 1994 created the regulatory framework; dietary supplements are regulated as foods, not drugs, unless disease claims are made (the statute defines the categories with dates and provisions)
04
EFSA guidance for health claims requires evidence in line with Regulation (EC) No 1924/2006; claim approvals depend on scientific substantiation standards (numeric regulation reference)
05
2021 China implemented GB standards for health food (and related GMP) that require numeric compliance testing for contaminants in functional products (standard framework includes numeric limits)
06
Japan FFC system (Food with Function Claims) requires notification; the number of FFC notifications exceeded 7,000 by 2023 (numerical count indicates regulatory throughput)
Interpretation
Regulation & Compliance Interpretation
Regulation and compliance for Ganoderma lucidum are tightening globally, with measurable milestones like more than 7,000 Japan FFC notifications by 2023 and over 30,000 ISO 22000 certificates worldwide by 2021 alongside stricter numeric contaminant limits and health claim evidence rules in the EU, US, and China.
06 · Category
Industry Overview10 stats
01
2024 industrial-grade Ganoderma lucidum extract ingredient procurement quotes commonly priced per kg of dry extract at roughly $50–$300 in US/Europe supplier catalogs (range stated in vendor price sheets)
02
2022 EU import tariffs for certain HS codes on mushroom products are 0% or low single digits, affecting reishi product landed cost depending on classification (tariff rates specified in TARIC tables)
03
2022 Chinese medicinal mushroom cultivation uses substrate materials; a cost model paper reported substrate costs as ~30–45% of total production cost for medicinal mushroom operations (substrate portion numeric)
04
A 2019 bioprocess economics study of Ganoderma lucidum liquid-state fermentation reported that fermentation feedstock and utilities together accounted for ~50–60% of operating cost (C/E breakdown included)
05
2020–2022 global inflation in shipping/inputs increased supplement production overhead; US producer price index for 'chemical manufacturing' rose over 20% cumulative in the period (proxy for extract production cost pressure)
06
2023: In the US, dietary supplement products are regulated under DSHEA, with 21 U.S.C. § 321(ff) defining dietary supplements (legal category affecting Ganoderma supplement labeling and claims)
07
2019: FDA-regulated dietary supplements were required to comply with Current Good Manufacturing Practice (CGMP) for dietary supplements under 21 CFR Part 111 (affects Ganoderma extract manufacture and documentation)
08
2019: EFSA set maximum levels for certain contaminants in foodstuffs; specific numeric maximum limits apply to lead in foods and food supplements in separate contaminant frameworks (relevance for Ganoderma supplement safety compliance)
09
2022: The EU Official Journal published Commission Regulation (EU) 2022/915 setting maximum levels of certain contaminants in food (numeric compliance thresholds relevant to mushroom-derived ingredients)
10
2020: The reishi (Ganoderma lucidum) extract market in China was reported at RMB 3.8 billion in a Chinese industry dataset (ingredient-level market estimate)
Interpretation
Industry Overview Interpretation
Across the ganoderma lucidum industry, ingredient pricing remains highly variable at about $50 to $300 per kg of dry extract while costs are shaped by cultivation and processing drivers such as substrate making up roughly 30 to 45% of production and added overhead from 2020 to 2022 shipping and input inflation, all within a US regulatory backdrop where dietary supplements are defined under DSHEA.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Ganoderma Lucidum Industry Statistics. Gitnux. https://gitnux.org/ganoderma-lucidum-industry-statistics
MLA
Aisha Okonkwo. "Ganoderma Lucidum Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ganoderma-lucidum-industry-statistics.
Chicago
Aisha Okonkwo. 2026. "Ganoderma Lucidum Industry Statistics." Gitnux. https://gitnux.org/ganoderma-lucidum-industry-statistics.
Sources & references
54 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)